Metformin use is associated with a reduced risk of glaucoma development among diabetics.
To examine whether the caloric restriction mimetic agent would be linked with a reduced risk of open-angle glaucoma in patients with diabetes, a team of researchers relied on a retrospective cohort of patients aged 40 years or older in a large US managed care network from 2001 to 2010. All 150,016 patients had diabetes and no preexisting record of open-angle glaucoma.
The researchers discovered that a total of 5893 patients (3.9%) from the cohort developed open-angle glaucoma over the study period. Those in the highest quartile of metformin hydrochloride use (>1110 g in 2 years) had a 25% reduced risk compared with those taking no metformin.
Every 1-g increase in metformin use was associated with a 0.16% reduction in open-angle glaucoma risk, the authors noted. They predicted that taking a standard dose of 2 g of metformin hydrochloride per day for 2 years would result in a 20.8% reduction in risk for open-angle glaucoma overall.